Lessons and Enlightments from International Experience of Health Insurance Drug Renewal Policy

Corresponding author: Wang Jian, wangjian993@whu.edu.cn

DOI: 10.12201/bmr.202407.00031

•  

  Abstract: Objective: Summarizing and analyzing the rules of access and renewal of drugs in Australia, Japan, South Korea, and Chinese Taiwan, this paper aims to provide experience for the improvement of Chinas policy of drug renewal list. Methods: Through literature review, expert interviews, and other academic methods, it compares the different experience of drug renewal policy from the perspectives of the type, content, and renewal period. Results: Internationally representative national or regional medical insurance drug renewal policies are broadly categorized into single-drug price-volume agreements, joint price-volume agreements, and efficacy-based risk-sharing agreements. Conclusion: It is recommended that China should introduce new content such as joint measurement for renewal of exclusive drugs, combination consideration of quantity, price, and effectiveness, risk-sharing agreement for renewal of non-exclusive drugs, and placing an upper limit on the rate of reduction for the first renewal in its medical insurance policy.

  Key words: Renewal; Risk-sharing agreement; Joint measurement; Price-volume agreement

  Submit time: 15 July 2024

  Copyright: The copyright holder for this preprint is the author/funder, who has granted biomedRxiv a license to display the preprint in perpetuity.
• html

• 图表

• Deng Ziru, Wang Wei, Fu Chaowei, Yan Fei. International Experience and Implications of Antimicrobials Management Strategies from the One Health Perspective. 2021. doi: 10.12201/bmr.202105.00011

  CHEN Tong, JIANG Rong, SHAO Rong. Research and Enlightenment on Canadian Pharmaceutical Rebates Agreements. 2021. doi: 10.12201/bmr.202101.00019

  WangBiao, Zhang Tiantian, Tang Xiaoyu, Jia Yun, Luo Li. A study of price reduction sustainability in national volume-based drug procurement. 2023. doi: 10.12201/bmr.202305.00008

  ZHU Xiaoli, Huang Xinyue, WANG Yuheng. Policy text analysis of prefectural-level health insurance risk pooling in China from the perspective of policy tools. 2024. doi: 10.12201/bmr.202406.00020

  LIU MINGZHU, LU YUN. Research on the Implementation Effect of Expiration of National Pharmaceutical Centralized Volume-based Procurement Based on Intermittent Time Series: A Case Study of Hebei Province. 2023. doi: 10.12201/bmr.202306.00007

  CHEN Yingcun, tanhuawei. Financial Vulnerability and Risk Protection of Health Insurance Payments in the Countys Healthcare Alliance: Risk Identification, Empirical Mirroring and Policy Pathways. 2022. doi: 10.12201/bmr.202212.00003

  renlei, xiejinping, yangyifan, shaorong. The Inspiration of the Design of Drug Medical Insurance Payment Standard System in typical countries and regions for China——From the perspective of original drug management. 2024. doi: 10.12201/bmr.202409.00048

  Sun Yan, Zhu Zheng, Yang Li. Influencing factors analysis on price reduction in national volume-based drug procurement.. 2022. doi: 10.12201/bmr.202203.00008

  WangBiao, Zhang Tiantian, Tang Xiaoyu, Jia Yun, Luo Li. Research on the price difference and regional distribution of selected drugs in Chinas centralized procurement. 2023. doi: 10.12201/bmr.202306.00008

  SUN Wenjun, ZHAO Ziyin, CHENG Zheyu, LI Huining, ZHU He. Impact of the national centralized drug procurement policy on drug prices and utilization: a systematic review. 2023. doi: 10.12201/bmr.202303.00033

• ID	Submit time	Number	Download
  1	2024-03-25	bmr.202407.00031V1	Download

• Public  Anonymous  To author only Submit Comments